Re: Farmas USA
Pathwin, eso lo saque de un foro en Facebook
ZGNX
I just broke news Zogenix is eligible for a FDA Priority Review Voucher for Brabafen. Knight Theraputics just sold one to Gilead for $125M. I posted draft guidance on MarketWatch. They definitely qualify. Once Brabafen is approved, FDA will issue a Priority Review Voucher to Zogenix. They can use or sell it.
----
Michael Schubert It's an FDA program to incentivize drugmakers to make meds for rare tropical diseases or rare pediatric diseases. They get the voucher upon approval, they can either use it or sell it like Knight did. The last voucher sold before this went for $63 Million. By the time Brabafen is approved, Zogenix can sell theirs for $200+ MILLION. Buying that company is turning out to be a brilliant move.
---------
Todo indica que Zgnx no es solo Zohydro